Sample size determination in clinical trials with multiple co-primary binary endpoints

被引:45
|
作者
Sozu, Takashi [1 ,2 ]
Sugimoto, Tomoyuki [2 ]
Hamasaki, Toshimitsu [1 ,2 ]
机构
[1] Osaka Univ, Ctr Adv Med Engn & Informat, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Dept Biomed Stat, Grad Sch Med, Suita, Osaka 5650871, Japan
关键词
correlated endpoints; multivariate Bernoulli; association measures; continuity correction; arcsine transformation; Fisher's exact method; EFFICACY; DESIGN; ISSUES; POWER;
D O I
10.1002/sim.3972
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Clinical trials often employ two or more primary efficacy endpoints. One of the major problems in such trials is how to determine a sample size suitable for multiple co-primary correlated endpoints. We provide fundamental formulae for the calculation of power and sample size in order to achieve statistical significance for all the multiple primary endpoints given as binary variables. On the basis of three association measures among primary endpoints, we discuss five methods of power and sample size calculation: the asymptotic normal method with and without continuity correction, the arcsine method with and without continuity correction, and Fisher's exact method. For all five methods, the achieved sample size decreases as the value of association measure increases when the effect sizes among endpoints are approximately equal. In particular, a high positive association has a greater effect on the decrease in the sample size. On the other hand, such a relationship is not very strong when the effect sizes are different. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:2169 / 2179
页数:11
相关论文
共 50 条
  • [31] Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power
    Jiaying Yang
    Guochun Li
    Dongqing Yang
    Juan Wu
    Junqin Wang
    Xingsu Gao
    Pei Liu
    BMC Medical Research Methodology, 24
  • [32] Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power
    Yang, Jiaying
    Li, Guochun
    Yang, Dongqing
    Wu, Juan
    Wang, Junqin
    Gao, Xingsu
    Liu, Pei
    BMC MEDICAL RESEARCH METHODOLOGY, 2024, 24 (01)
  • [33] A stratified adaptive two-stage design with co-primary endpoints for phase II clinical oncology trials
    Cabarrou, Bastien
    Leconte, Eve
    Sfumato, Patrick
    Boher, Jean-Marie
    Filleron, Thomas
    BMC MEDICAL RESEARCH METHODOLOGY, 2022, 22 (01)
  • [34] A stratified adaptive two-stage design with co-primary endpoints for phase II clinical oncology trials
    Bastien Cabarrou
    Eve Leconte
    Patrick Sfumato
    Jean-Marie Boher
    Thomas Filleron
    BMC Medical Research Methodology, 22
  • [35] Power estimation for multiple co-primary endpoints: a comparison among conservative solutions
    Lucadamo, Antonio
    Accoto, Nadia
    De Martini, Daniele
    EPIDEMIOLOGY BIOSTATISTICS AND PUBLIC HEALTH, 2012, 9 (04):
  • [36] A testing procedure in clinical trials with multiple binary endpoints
    Ishihara, Takuma
    Yamamoto, Kouji
    COMMUNICATIONS IN STATISTICS-THEORY AND METHODS, 2023, 52 (02) : 273 - 282
  • [37] Sample Size Determination for Equivalence Assessment with Multiple Endpoints
    Sun, Anna
    Dong, Xiaoyu
    Tsong, Yi
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (06) : 1203 - 1214
  • [38] Sample size determination and re-estimation for matched pair designs with multiple binary endpoints
    Xu, Jin
    Yu, Menggang
    BIOMETRICAL JOURNAL, 2013, 55 (03) : 430 - 443
  • [39] A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints
    Sugimoto, Tomoyuki
    Sozu, Takashi
    Hamasaki, Toshimitsu
    Evans, Scott R.
    BIOSTATISTICS, 2013, 14 (03) : 409 - 421
  • [40] Sample size calculation for complex clinical trials with survival endpoints
    Shih, JH
    CONTROLLED CLINICAL TRIALS, 1995, 16 (06): : 395 - 407